| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukoencephalopathy, Progressive Multifocal | 40 | 2021 | 44 | 9.350 |
Why?
|
| JC Virus | 33 | 2019 | 39 | 7.940 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2023 | 54 | 2.190 |
Why?
|
| Humans | 81 | 2023 | 12240 | 2.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2023 | 61 | 1.930 |
Why?
|
| Polyomavirus Infections | 8 | 2017 | 9 | 1.770 |
Why?
|
| AIDS-Related Opportunistic Infections | 7 | 2015 | 16 | 1.680 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 40 | 1.650 |
Why?
|
| Neurology | 3 | 2022 | 16 | 1.640 |
Why?
|
| Brain Diseases | 5 | 2021 | 30 | 1.440 |
Why?
|
| Capsid Proteins | 6 | 2014 | 8 | 1.390 |
Why?
|
| Male | 40 | 2021 | 6815 | 1.340 |
Why?
|
| DNA, Viral | 11 | 2014 | 25 | 1.330 |
Why?
|
| Tuberculosis, Meningeal | 2 | 2021 | 3 | 1.300 |
Why?
|
| Multiple Sclerosis | 4 | 2020 | 32 | 1.290 |
Why?
|
| Adult | 28 | 2021 | 3557 | 1.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 2015 | 26 | 1.180 |
Why?
|
| Remote Consultation | 2 | 2022 | 5 | 1.160 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2014 | 464 | 1.060 |
Why?
|
| Nervous System Diseases | 3 | 2021 | 60 | 1.050 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2012 | 3 | 1.040 |
Why?
|
| Middle Aged | 24 | 2021 | 4043 | 1.020 |
Why?
|
| HIV Infections | 11 | 2020 | 256 | 0.990 |
Why?
|
| Immunity, Cellular | 6 | 2013 | 14 | 0.960 |
Why?
|
| Female | 27 | 2021 | 6974 | 0.920 |
Why?
|
| Immunologic Factors | 3 | 2021 | 6 | 0.910 |
Why?
|
| Seizures | 4 | 2020 | 35 | 0.900 |
Why?
|
| Neurons | 3 | 2015 | 164 | 0.870 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 3 | 2014 | 6 | 0.870 |
Why?
|
| Brain | 11 | 2020 | 707 | 0.840 |
Why?
|
| Internship and Residency | 2 | 2017 | 103 | 0.820 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2015 | 10 | 0.800 |
Why?
|
| Young Adult | 10 | 2021 | 863 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 3 | 2022 | 86 | 0.780 |
Why?
|
| Viral Regulatory and Accessory Proteins | 3 | 2013 | 7 | 0.770 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2009 | 9 | 0.760 |
Why?
|
| Zambia | 7 | 2022 | 9 | 0.760 |
Why?
|
| Interferon-gamma | 2 | 2019 | 26 | 0.710 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2019 | 6 | 0.700 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 7 | 0.700 |
Why?
|
| Retrospective Studies | 9 | 2023 | 1467 | 0.670 |
Why?
|
| Genotype | 1 | 2021 | 169 | 0.670 |
Why?
|
| Dysgeusia | 1 | 2020 | 1 | 0.650 |
Why?
|
| Myalgia | 1 | 2020 | 1 | 0.650 |
Why?
|
| Dizziness | 1 | 2020 | 9 | 0.650 |
Why?
|
| Headache | 1 | 2020 | 22 | 0.640 |
Why?
|
| Olfaction Disorders | 1 | 2020 | 24 | 0.640 |
Why?
|
| Narcolepsy | 1 | 2019 | 2 | 0.610 |
Why?
|
| Orexins | 1 | 2019 | 2 | 0.610 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 45 | 0.610 |
Why?
|
| Autoimmunity | 1 | 2019 | 8 | 0.610 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 48 | 0.610 |
Why?
|
| Natalizumab | 6 | 2019 | 8 | 0.600 |
Why?
|
| Immunoassay | 1 | 2019 | 18 | 0.600 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 41 | 0.590 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 95 | 0.590 |
Why?
|
| Capsid | 3 | 2014 | 6 | 0.570 |
Why?
|
| T-Lymphocytes | 3 | 2014 | 50 | 0.550 |
Why?
|
| Anti-Retroviral Agents | 2 | 2015 | 11 | 0.550 |
Why?
|
| Prospective Studies | 5 | 2023 | 817 | 0.530 |
Why?
|
| Aged | 14 | 2021 | 4000 | 0.530 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2008 | 6 | 0.510 |
Why?
|
| Global Health | 1 | 2017 | 11 | 0.500 |
Why?
|
| Health Resources | 1 | 2017 | 14 | 0.500 |
Why?
|
| Program Development | 1 | 2017 | 26 | 0.500 |
Why?
|
| Thymus Gland | 1 | 2015 | 10 | 0.470 |
Why?
|
| Disease Progression | 5 | 2023 | 290 | 0.460 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 2 | 0.460 |
Why?
|
| Genes, Reporter | 1 | 2015 | 15 | 0.450 |
Why?
|
| Viral Proteins | 1 | 2015 | 7 | 0.450 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 77 | 0.450 |
Why?
|
| Dura Mater | 1 | 2015 | 9 | 0.440 |
Why?
|
| Rare Diseases | 1 | 2015 | 6 | 0.440 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 2152 | 0.430 |
Why?
|
| Animals | 9 | 2022 | 2092 | 0.430 |
Why?
|
| Sequence Deletion | 2 | 2012 | 7 | 0.420 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2007 | 6 | 0.420 |
Why?
|
| Herpesviridae | 1 | 2014 | 2 | 0.420 |
Why?
|
| Central Nervous System Infections | 1 | 2014 | 4 | 0.420 |
Why?
|
| Virus Diseases | 1 | 2014 | 6 | 0.410 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2013 | 132 | 0.410 |
Why?
|
| DNA | 1 | 2014 | 57 | 0.410 |
Why?
|
| Inflammation | 2 | 2013 | 124 | 0.410 |
Why?
|
| Virus Assembly | 1 | 2013 | 3 | 0.410 |
Why?
|
| Virion | 1 | 2013 | 7 | 0.400 |
Why?
|
| Bacterial Infections | 1 | 2014 | 26 | 0.400 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2013 | 10 | 0.400 |
Why?
|
| Methylprednisolone | 1 | 2012 | 10 | 0.380 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 55 | 0.360 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2012 | 20 | 0.360 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 31 | 0.360 |
Why?
|
| Survival Rate | 4 | 2021 | 152 | 0.360 |
Why?
|
| Molecular Sequence Data | 8 | 2012 | 100 | 0.350 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 1 | 0.350 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 6 | 0.350 |
Why?
|
| Coinfection | 1 | 2011 | 6 | 0.350 |
Why?
|
| Viral Load | 6 | 2020 | 43 | 0.340 |
Why?
|
| Genes, Viral | 2 | 2012 | 4 | 0.340 |
Why?
|
| Tandem Repeat Sequences | 3 | 2012 | 4 | 0.330 |
Why?
|
| Prognosis | 5 | 2021 | 363 | 0.330 |
Why?
|
| Quality of Life | 2 | 2023 | 261 | 0.330 |
Why?
|
| Risk Factors | 5 | 2020 | 1049 | 0.330 |
Why?
|
| Pandemics | 2 | 2022 | 126 | 0.320 |
Why?
|
| Opportunistic Infections | 2 | 2009 | 4 | 0.320 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 3 | 0.320 |
Why?
|
| Developing Countries | 1 | 2010 | 7 | 0.310 |
Why?
|
| Communicable Diseases | 1 | 2010 | 7 | 0.310 |
Why?
|
| COS Cells | 3 | 2014 | 22 | 0.310 |
Why?
|
| Immune Tolerance | 1 | 2009 | 6 | 0.310 |
Why?
|
| Genome, Viral | 2 | 2012 | 8 | 0.300 |
Why?
|
| Integrin alpha4 | 1 | 2009 | 1 | 0.300 |
Why?
|
| Virus Activation | 1 | 2009 | 4 | 0.300 |
Why?
|
| Hospitals | 1 | 2010 | 68 | 0.300 |
Why?
|
| Prevalence | 3 | 2021 | 175 | 0.300 |
Why?
|
| Terminology as Topic | 2 | 2006 | 15 | 0.290 |
Why?
|
| HIV Seropositivity | 3 | 2004 | 36 | 0.280 |
Why?
|
| Bone Marrow | 1 | 2008 | 35 | 0.280 |
Why?
|
| Lymphoma | 2 | 2007 | 16 | 0.280 |
Why?
|
| Genetic Variation | 2 | 2006 | 44 | 0.270 |
Why?
|
| Adolescent | 4 | 2019 | 989 | 0.260 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2019 | 11 | 0.250 |
Why?
|
| Amino Acid Sequence | 5 | 2012 | 80 | 0.240 |
Why?
|
| Epilepsy | 2 | 2020 | 36 | 0.230 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 726 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 57 | 0.230 |
Why?
|
| Neuroimaging | 3 | 2021 | 66 | 0.220 |
Why?
|
| Kidney Transplantation | 3 | 2017 | 51 | 0.220 |
Why?
|
| Anticonvulsants | 2 | 2020 | 30 | 0.220 |
Why?
|
| HIV-2 | 2 | 2004 | 3 | 0.220 |
Why?
|
| Chicago | 3 | 2022 | 453 | 0.220 |
Why?
|
| Cell Line | 3 | 2015 | 150 | 0.220 |
Why?
|
| Kidney | 2 | 2017 | 87 | 0.220 |
Why?
|
| Recombination, Genetic | 2 | 2015 | 3 | 0.220 |
Why?
|
| Inositol | 1 | 2004 | 3 | 0.210 |
Why?
|
| BK Virus | 1 | 2004 | 1 | 0.210 |
Why?
|
| Capillary Leak Syndrome | 1 | 2004 | 1 | 0.210 |
Why?
|
| Aspartic Acid | 1 | 2004 | 6 | 0.210 |
Why?
|
| Cerebellum | 3 | 2013 | 17 | 0.210 |
Why?
|
| Base Sequence | 4 | 2012 | 57 | 0.210 |
Why?
|
| Paresis | 1 | 2004 | 6 | 0.210 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2010 | 14 | 0.210 |
Why?
|
| Biomarkers | 3 | 2012 | 294 | 0.200 |
Why?
|
| Immunity | 1 | 2023 | 5 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2021 | 1478 | 0.200 |
Why?
|
| Child | 2 | 2019 | 614 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2021 | 256 | 0.190 |
Why?
|
| Stroke | 2 | 2020 | 117 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2023 | 48 | 0.190 |
Why?
|
| Fatigue | 1 | 2023 | 25 | 0.190 |
Why?
|
| Encephalitis | 2 | 2014 | 8 | 0.190 |
Why?
|
| Nucleocapsid | 1 | 2022 | 2 | 0.190 |
Why?
|
| Interferon-beta | 2 | 2014 | 3 | 0.190 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2020 | 32 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 400 | 0.170 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 18 | 0.170 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2021 | 1 | 0.170 |
Why?
|
| Drug Resistance, Viral | 2 | 2020 | 7 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 110 | 0.170 |
Why?
|
| New York City | 1 | 2021 | 3 | 0.170 |
Why?
|
| Bayes Theorem | 1 | 2021 | 10 | 0.170 |
Why?
|
| Herpesviridae Infections | 1 | 2001 | 1 | 0.170 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2001 | 1 | 0.170 |
Why?
|
| Herpesvirus 8, Human | 1 | 2001 | 1 | 0.170 |
Why?
|
| Herpesvirus 6, Human | 1 | 2001 | 2 | 0.170 |
Why?
|
| Herpesvirus 7, Human | 1 | 2001 | 2 | 0.170 |
Why?
|
| Morbidity | 1 | 2021 | 33 | 0.170 |
Why?
|
| Neurologic Examination | 2 | 2012 | 49 | 0.170 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2000 | 2 | 0.170 |
Why?
|
| Pharmacovigilance | 1 | 2020 | 1 | 0.170 |
Why?
|
| Intracranial Embolism | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 7 | 0.170 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2020 | 7 | 0.160 |
Why?
|
| Carbamazepine | 1 | 2020 | 2 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 23 | 0.160 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 24 | 0.160 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 43 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2020 | 32 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 35 | 0.160 |
Why?
|
| Mortality | 1 | 2020 | 37 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 38 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 46 | 0.160 |
Why?
|
| Human T-lymphotropic virus 1 | 3 | 1994 | 3 | 0.160 |
Why?
|
| Ataxia | 1 | 2020 | 51 | 0.150 |
Why?
|
| Olive Oil | 1 | 2019 | 1 | 0.150 |
Why?
|
| Antigens, Viral | 2 | 2013 | 5 | 0.150 |
Why?
|
| Reagent Strips | 1 | 2019 | 1 | 0.150 |
Why?
|
| Glucose | 1 | 2019 | 24 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 46 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2012 | 9 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 423 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 252 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2011 | 28 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 324 | 0.140 |
Why?
|
| Cerebrospinal Fluid | 3 | 2009 | 5 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2017 | 1 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 59 | 0.130 |
Why?
|
| Toxoplasmosis | 2 | 2014 | 5 | 0.130 |
Why?
|
| Cryptococcosis | 2 | 2014 | 6 | 0.130 |
Why?
|
| Mice | 3 | 2022 | 760 | 0.120 |
Why?
|
| Antiviral Agents | 2 | 2015 | 27 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2017 | 119 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 28 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 18 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 89 | 0.110 |
Why?
|
| Consensus | 2 | 2013 | 47 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2014 | 62 | 0.110 |
Why?
|
| Transfection | 1 | 2014 | 59 | 0.110 |
Why?
|
| Interferon beta-1a | 1 | 2014 | 2 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 47 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2014 | 51 | 0.100 |
Why?
|
| Deltaretrovirus Infections | 1 | 1994 | 1 | 0.100 |
Why?
|
| Simian T-lymphotropic virus 1 | 1 | 1994 | 1 | 0.100 |
Why?
|
| Genes, env | 1 | 1994 | 1 | 0.100 |
Why?
|
| Haplorhini | 1 | 1994 | 6 | 0.100 |
Why?
|
| DNA, Fungal | 1 | 2014 | 2 | 0.100 |
Why?
|
| Neisseria meningitidis | 1 | 2014 | 2 | 0.100 |
Why?
|
| DNA, Protozoan | 1 | 2014 | 3 | 0.100 |
Why?
|
| Cerebellar Ataxia | 1 | 2014 | 3 | 0.100 |
Why?
|
| Cryptococcus | 1 | 2014 | 3 | 0.100 |
Why?
|
| Phylogeny | 3 | 2004 | 35 | 0.100 |
Why?
|
| Streptococcus pneumoniae | 1 | 2014 | 3 | 0.100 |
Why?
|
| Toxoplasma | 1 | 2014 | 5 | 0.100 |
Why?
|
| Immunosuppressive Agents | 3 | 2017 | 61 | 0.100 |
Why?
|
| DNA, Bacterial | 1 | 2014 | 22 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 15 | 0.100 |
Why?
|
| Gene Order | 1 | 2013 | 2 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2013 | 26 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 3 | 0.100 |
Why?
|
| Neuroglia | 1 | 2013 | 19 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 9 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 651 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 53 | 0.100 |
Why?
|
| Virus Replication | 1 | 2013 | 29 | 0.100 |
Why?
|
| Mutation | 1 | 2014 | 175 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 4 | 0.100 |
Why?
|
| Pons | 1 | 2013 | 4 | 0.100 |
Why?
|
| Antigens, Differentiation | 1 | 2013 | 4 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 9 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 16 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2013 | 24 | 0.100 |
Why?
|
| Phenotype | 1 | 2013 | 157 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 338 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 218 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2004 | 33 | 0.100 |
Why?
|
| Biopsy | 3 | 2017 | 97 | 0.100 |
Why?
|
| Viral Core Proteins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Genes, Regulator | 1 | 2012 | 3 | 0.090 |
Why?
|
| Alcoholic Intoxication | 1 | 2012 | 4 | 0.090 |
Why?
|
| Viral Tropism | 1 | 2012 | 3 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 30 | 0.090 |
Why?
|
| Atrophy | 1 | 2012 | 29 | 0.090 |
Why?
|
| Time Factors | 1 | 2014 | 695 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 151 | 0.090 |
Why?
|
| Pyramidal Cells | 1 | 2012 | 28 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 61 | 0.090 |
Why?
|
| Spinal Cord | 1 | 2012 | 46 | 0.090 |
Why?
|
| Antiprotozoal Agents | 1 | 2011 | 7 | 0.090 |
Why?
|
| Facial Hemiatrophy | 1 | 2011 | 1 | 0.090 |
Why?
|
| Meningitis, Aseptic | 1 | 1991 | 1 | 0.090 |
Why?
|
| Nervous System | 1 | 1990 | 4 | 0.080 |
Why?
|
| Tremor | 1 | 2011 | 60 | 0.080 |
Why?
|
| Antigens | 1 | 2010 | 3 | 0.080 |
Why?
|
| Sequence Alignment | 2 | 2004 | 8 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2004 | 17 | 0.080 |
Why?
|
| HLA-A3 Antigen | 1 | 2010 | 1 | 0.080 |
Why?
|
| HLA-B18 Antigen | 1 | 2010 | 1 | 0.080 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 2 | 0.080 |
Why?
|
| Serotyping | 1 | 2010 | 6 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 3 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 4 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 33 | 0.080 |
Why?
|
| HIV | 1 | 2010 | 20 | 0.080 |
Why?
|
| Lymphopenia | 1 | 2009 | 2 | 0.080 |
Why?
|
| HIV Seronegativity | 1 | 2009 | 10 | 0.080 |
Why?
|
| Urine | 1 | 2009 | 1 | 0.080 |
Why?
|
| Viremia | 1 | 2009 | 3 | 0.080 |
Why?
|
| Outpatients | 1 | 2010 | 24 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 2010 | 21 | 0.080 |
Why?
|
| AIDS Dementia Complex | 1 | 2010 | 31 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 60 | 0.070 |
Why?
|
| Inpatients | 1 | 2010 | 56 | 0.070 |
Why?
|
| Comorbidity | 1 | 2010 | 209 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2020 | 15 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 60 | 0.070 |
Why?
|
| Pregnancy | 1 | 2009 | 193 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 182 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2009 | 214 | 0.070 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 5 | 0.070 |
Why?
|
| Dermatomyositis | 1 | 2006 | 5 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 68 | 0.060 |
Why?
|
| Risk | 1 | 2006 | 97 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 99 | 0.060 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2004 | 1 | 0.050 |
Why?
|
| Creatine | 1 | 2004 | 2 | 0.050 |
Why?
|
| Choline | 1 | 2004 | 2 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2004 | 2 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2004 | 2 | 0.050 |
Why?
|
| Simian virus 40 | 1 | 2004 | 1 | 0.050 |
Why?
|
| Survivors | 1 | 2004 | 27 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2004 | 1 | 0.050 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 7 | 0.050 |
Why?
|
| Meningoencephalitis | 1 | 2004 | 4 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 10 | 0.050 |
Why?
|
| Epitopes | 1 | 2004 | 17 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2004 | 25 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2004 | 1 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 72 | 0.050 |
Why?
|
| Heart | 1 | 2004 | 42 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2004 | 37 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2004 | 31 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 258 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 11 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 201 | 0.050 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 25 | 0.040 |
Why?
|
| Income | 1 | 2022 | 35 | 0.040 |
Why?
|
| Nerve Growth Factor | 1 | 2001 | 25 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2001 | 1 | 0.040 |
Why?
|
| Phrenic Nerve | 1 | 2021 | 1 | 0.040 |
Why?
|
| Diaphragm | 1 | 2021 | 3 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 62 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2020 | 2 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2020 | 4 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2020 | 8 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 16 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 19 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2020 | 19 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 23 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2020 | 42 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 158 | 0.040 |
Why?
|
| Skin | 1 | 2001 | 73 | 0.040 |
Why?
|
| Reoperation | 2 | 2017 | 366 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 82 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 152 | 0.040 |
Why?
|
| Phlebography | 1 | 2017 | 3 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 13 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1994 | 18 | 0.030 |
Why?
|
| Species Specificity | 2 | 1994 | 28 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2017 | 23 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2017 | 17 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 84 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 171 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 827 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1996 | 1 | 0.030 |
Why?
|
| Eye Movements | 1 | 1996 | 6 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1996 | 13 | 0.030 |
Why?
|
| HIV-1 | 1 | 2017 | 143 | 0.030 |
Why?
|
| Cercopithecidae | 1 | 1994 | 1 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 1994 | 2 | 0.030 |
Why?
|
| Cytoplasmic Granules | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 4 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 1994 | 3 | 0.030 |
Why?
|
| Rituximab | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1993 | 1 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1993 | 2 | 0.030 |
Why?
|
| United States | 1 | 2017 | 989 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2014 | 67 | 0.020 |
Why?
|
| Transcription Factors | 1 | 1993 | 105 | 0.020 |
Why?
|
| Oligodendroglia | 1 | 2013 | 12 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 156 | 0.020 |
Why?
|
| Oligoclonal Bands | 1 | 2011 | 1 | 0.020 |
Why?
|
| Vasculitis | 1 | 1991 | 17 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1991 | 20 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1991 | 35 | 0.020 |
Why?
|
| Electronystagmography | 1 | 1990 | 1 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 1990 | 1 | 0.020 |
Why?
|
| Homosexuality | 1 | 1990 | 4 | 0.020 |
Why?
|
| Audiometry | 1 | 1990 | 2 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1990 | 4 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1990 | 35 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1990 | 16 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1990 | 32 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2006 | 1 | 0.020 |
Why?
|
| Mianserin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Cytarabine | 1 | 2006 | 5 | 0.020 |
Why?
|
| Meninges | 1 | 2004 | 2 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2004 | 11 | 0.010 |
Why?
|
| Polyomavirus | 1 | 2004 | 1 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2004 | 30 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 86 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 32 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 90 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2001 | 211 | 0.010 |
Why?
|
| Blepharoptosis | 1 | 1996 | 1 | 0.010 |
Why?
|
| Convergence, Ocular | 1 | 1996 | 1 | 0.010 |
Why?
|
| Exotropia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Ophthalmoplegia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Americas | 1 | 1994 | 1 | 0.010 |
Why?
|
| HTLV-I Infections | 1 | 1994 | 1 | 0.010 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1993 | 1 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1993 | 6 | 0.010 |
Why?
|
| Proton-Translocating ATPases | 1 | 1993 | 3 | 0.010 |
Why?
|
| Vacuoles | 1 | 1993 | 3 | 0.010 |
Why?
|